| 1 |
Thomas R, Roy B, Maldonado F, et al. Management of malignant pleural effusions-what is new[J]. Semin Respir Crit Care Med, 2019, 40 (3): 323-339.
|
| 2 |
Walker S, Mercer R, Maskell N, et al. Malignant pleural effusion management: keeping the flood gates shut[J]. Lancet Respir Med, 2019, pii: S2213-2600 (19)30373-X.
|
| 3 |
刘丽华，马想明，周红梅，等. 恶性胸腔积液临床中西医诊治研究进展[J]. 甘肃科技纵横，2018, 47(3): 74-79.
|
| 4 |
李 佳，殷东风. 殷东风教授治疗恶性肿瘤患者水液代谢失常经验介绍[J]. 新中医，2007, 5: 94-95.
|
| 5 |
Dai FH, Gao X, Li HY, et al. Evaluation of efficacy and safety for Brucea javanica oil emulsion in the control of the malignant pleural effusions via thoracic perfusion[J]. BMC Cancer, 2018, 18(1): 411.
|
| 6 |
Tian AP, Yin YK, Yu L, et al. Low-frequency sonophoresis of Chinese Medicine formula improves efficacy of malignant pleural effusion treatment[J]. Chin J Integr Med, 2019, doi: 10.1007/s11655-019-3167-7. |
| 7 |
Skok K, Hladnik G, Grm A, et al. Malignant pleural effusion and its current management: A review[J]. Medicina (Kaunas), 2019, 55(8): 490.
|
| 8 |
Donnenberg AD, Luketich JD, Dhupar R, et al. Treatment of malignant pleural effusions: the case for localized immunotherapy[J]. J Immunother Cancer, 2019, 7(1): 110.
|
| 9 |
Murthy P, Ekeke CN, Russell KL, et al. Making cold malignant pleural effusions hot: driving novel immunotherapies[J]. Oncoimmunology, 2019, 22, 8(4): e1554969.
|
| 10 |
Wang D, Yang L, Yue D, et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion[J]. Cancer Lett, 2019, 452: 244-253.
|
| 11 |
Choi MG, Park S, Oh DK, et al. Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study[J]. Thorac Cancer, 2019, 10(10): 1885-1892.
|
| 12 |
Sivakumar P, Saigal A, Ahmed L. Quality of life after interventions for malignant pleural effusions: a systematic review[J]. BMJ Support Palliat Care, 2019, 10(1): 45-54..
|
| 13 |
Migliore M, Nardini M. Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lung cancer and malignant pleural effusion？[J]. Eur Respir Rev, 2019, 28(153). pii: 190018.
|
| 14 |
Kleontas A, Sioga A, Pandria N, et al. Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial[J]. J Thorac Dis, 2019, 11(5): 1788-1798.
|
| 15 |
Syer T, Walker S, Maskell N. The use of indwelling pleural catheters for the treatment of malignant pleural effusions[J]. Expert Rev Respir Med, 2019, 13(7): 659-664.
|
| 16 |
Dipper A, Bhatnagar R, Maskell N. Outpatient talc administration via indwelling pleural catheters for malignant effusions[J]. Curr Opin Pulm Med, 2019, 25(4): 380-383.
|
| 17 |
Lan NSH, Vekaria S, Sidhu C, et al. Very low-dose intrapleural tPA for indwelling pleural catheter-associated symptomatic fluid loculation[J]. Respirol Case Rep, 2019, 7(7): e00457.
|
| 18 |
Nie K, Zhang Z, You Y, et al. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer[J]. Thorac Cancer, 2020, 11(1): 8-14.
|
| 19 |
Zhang W, Williams TA, Bhagwath AS, et al. GEAMP, a novel gastroesophageal junction carcinoma cell line derived from a malignant pleural effusion[J]. Lab Invest, 2020, 100(1): 16-26.
|
| 20 |
Foote DC, Burke CR, Pandian B, et al. Gender disparity in referral for definitive care of malignant pleural effusions[J]. J Surg Res, 2019, 244: 409-416.
|
| 21 |
Wang W, Jiang X, Zhang Y, et al. Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients[J]. J Thorac Dis, 2019, 11(9): 3712-3720.
|
| 22 |
Mitchell MA, Dhaliwal I, Mulpuru S, et al. Early readmission to hospital in patients with cancer with malignant pleural effusions: Analysis of the nationwide readmissions database[J]. Chest, 2020, 157(2): 435-445.
|
| 23 |
Wang S, Chen H, Zhong J, et al. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung[J]. Lung Cancer, 2019, 135: 116-122.
|
| 24 |
Awadallah SF, Bowling MR, Sharma N, et al. Malignant pleural effusion and cancer of unknown primary site: a review of literature[J]. Ann Transl Med, 2019, 7(15): 353.
|
| 25 |
Birnie KA, Prêle CM, Musk AWB, et al. MicroRNA signatures in malignant pleural mesothelioma effusions[J]. Dis Markers, 2019, 2019: 8628612.
|
| 26 |
Halimi M, BeheshtiRouy S, Salehi D, et al. The role of immunohistochemistry studies in distinguishing malignant mesothelioma from metastatic lung carcinoma in malignant pleural effusion[J]. Iran J Pathol, 2019, 14(2): 122-126.
|
| 27 |
Tang Y, Zhang J, Huang H, et al. Pleural IFN-γ release assay combined with biomarkers distinguished effectively tuberculosis from malignant pleural effusion[J]. BMC Infect Dis, 2019, 19(1): 55.
|
| 28 |
Shibaki R, Murakami S, Shinno Y, et al. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer[J]. Thorac Cancer, 2019, 10(4): 815-822.
|
| 29 |
Hiranuma O, Uchino J, Yamada T, et al. Rationale and design of a phase Ⅱ trial of osimertinib combined with Bevacizumab in patients with untreated epidermal growth factor receptor-mutated non-small-cell lung cancer and malignant pleural and/or pericardial effusion(SPIRAL Ⅱ Study)[J]. Clin Lung Cancer, 2019, 20(3): E402-e406.
|